Rolls-Royce Stock Tries to Stabilize as Investors Test the Limits of the Turnaround

May 13, 2026
Rolls-Royce Stock Tries to Stabilize as Investors Test the Limits of the Turnaround

London, May 13, 2026, 10:04 (BST)

  • Rolls-Royce picked up roughly 0.6% to 1,197.60p in London, recouping only a slice of Tuesday’s 2.98% drop to 1,191p. This is more a patch-up than a turnaround.
  • Berenberg bumped its target on the stock to 1,270p but stuck with a “hold” call, pointing to strong operational guidance facing off against a valuation reality check. Rolls-Royce is still pulling shares from circulation through its buyback. MarketBeat
  • Bulls cite engine flying hours, cash flow, and the ongoing surge in data-centre power demand. Bears flag the risks tied to widebody aircraft, Middle East troubles, and a chart that’s been drifting lower since peaking in February.

Rolls-Royce Holdings plc ticked up in London on Wednesday, hovering near 1,197.60p after ending Tuesday at 1,191p. The stock barely budged within its session, moving between 1,195.60p and 1,215.60p. That’s significant—1,190p remains the pivot to watch, with the chart more focused on defending that level than pushing higher.

This move is really about the market taking a breather. Shares slid 2.98% on Tuesday, lagging a nearly unchanged FTSE 100, after some volatile action: up 6.42% on May 6, then three back-to-back down days later in the week. That pretty much sums it up—investors aren’t bailing on the turnaround, but they’ve stopped chasing unless there’s something new to go on.

The catalyst gap remains front and center. Berenberg nudged its target price up to 1,270p from 1,250p, sticking with its hold call—a sign, perhaps, that the big rerating has cooled enthusiasm for further near-term gains. MarketBeat’s numbers point to a Moderate Buy consensus, with the street averaging a 1,390.20p target. Still, the shares are already priced for plenty.

Rolls-Royce remains focused on boosting its equity narrative with direct cash returns. The group disclosed it snapped up 1.8 million shares between May 5 and May 11, moving forward with its £2.3 billion buyback plan. That brings the total to 52.7 million shares repurchased so far, at a 1,201.13p weighted average. Cutting the share count can push up earnings per share, but questions about the cycle haven’t gone away.

Management struck a decisive note. In the April 30 trading update, Chief Executive Tufan Erginbilgic said Rolls-Royce aims to “fully mitigate the current financial impact” from Middle East disruption, and the company maintained its 2026 targets: underlying operating profit between £4.0 billion and £4.2 billion, free cash flow at £3.6 billion to £3.8 billion. Free cash flow—what remains after covering operating requirements and capex—goes to buybacks, dividends, debt. Rolls-Royce

Engine flying hours, or EFH, still set the tone—this is the number of hours Rolls-Royce engines are actually in the air, and it’s a core piece of the company’s aftermarket business. Large EFH hit 115% of where things stood in 2019 during the first quarter, according to Rolls. Flying hours for Trent XWB engines at Middle Eastern carriers are already back at pre-conflict marks. That’s part of why shares can hold up, even with rough geopolitical news in the mix.

Middle East risk hasn’t disappeared. Over on Polymarket’s Iran markets, traders have pegged a 23% chance that the U.S. will announce the Strait of Hormuz blockade is over by May 31. By June 30, they’re pricing in 52% odds—a snapshot of just how unsettled the route-and-fuel situation looks. That’s not a direct hit for Rolls-Royce, but it’s not trivial: whenever fuel prices surge or airlines face detours, airline capacity can shrink, pulling down engine hours.

Bulls are latching onto one thing: this isn’t just about civil aerospace bouncing back anymore. Power Systems posted a roughly 50% jump in first-quarter orders for gas and diesel engines, fueled by data-centre demand. Defence and business aviation also got out of the gate quickly this year. That broader base offers investors more routes to back the cash-flow target.

Here’s the bear argument: concentration risk. Berenberg pointed to solid demand for the latest Trent engines, but the bank isn’t budging from a cautious stance—Rolls-Royce’s fate is still tied mostly to widebody jets. MTU Aero Engines was downgraded to hold, while Safran remains Berenberg’s favorite among aero-engine stocks. Bottom line, if there’s a slump in long-haul air travel, Rolls would feel it more than diversified peers.

Peer comparisons cut both ways. Rolls-Royce is targeting mid-term operating margins between 18% and 20%, matching up with GE Aerospace—the company’s primary competitor in the widebody engine business. That target looks plausible, given the recent turnaround. But it also pushes Rolls-Royce into a different bracket: investors now weigh it less as a UK turnaround story and more alongside global aerospace heavyweights.

Debt markets introduce fresh complexity. Rolls-Royce is lining up its first euro bond issue since 2020, aiming to shore up its financial position as Middle East turbulence continues. On the face of it, improved market access looks good for the balance sheet. But the fact that management keeps adding cushions signals ongoing unease about the wider environment.

The stock’s move today can’t be pinned to a single headline. This is a market pausing to reassess a name that’s already baked in plenty of turnaround hopes. The company keeps hitting targets, buybacks are ongoing, guidance is intact. Still, after the run-up, investors want to see actual cash, real engine hours, fresh orders—words from management aren’t cutting it anymore.

Stock Market Today

  • Hantavirus Outbreak Spurs Interest in Vaccine-Linked FTSE 100 Stock Croda
    May 13, 2026, 5:32 AM EDT. The recent hantavirus cases aboard an Argentine cruise ship have not triggered a market-wide panic but are reigniting investor focus on vaccine-related stocks. Moderna's shares climbed nearly 14% amid renewed vaccine development efforts targeting hantavirus. Significantly, Croda International, a FTSE 100 firm that supplies lipids crucial for mRNA vaccines, may see a resurgence after past pandemic-driven demand waned and poorly timed acquisitions weighed on performance. With inventory stabilization and rising vaccine study activity, Croda's shares could present a compelling opportunity. While hantavirus itself is unlikely to prompt a market crash akin to COVID-19's impact, its ripple effects in the pharmaceutical sector warrant investor attention.